ロード中...
NS5A Sequence Heterogeneity and Mechanisms of Daclatasvir Resistance in Hepatitis C Virus Genotype 4 Infection
Background. Daclatasvir is an NS5A inhibitor approved for treatment of infection due to hepatitis C virus (HCV) genotypes (GTs) 1–4. To support daclatasvir use in HCV genotype 4 infection, we examined a diverse genotype 4–infected population for HCV genotype 4 subtype prevalence, NS5A polymorphisms...
保存先:
| 出版年: | J Infect Dis |
|---|---|
| 主要な著者: | , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Oxford University Press
2016
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4690147/ https://ncbi.nlm.nih.gov/pubmed/26170396 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/infdis/jiv379 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|